Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution
- 13 August 2018
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 138 (7), 743-745
- https://doi.org/10.1161/CIRCULATIONAHA.118.035898
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditisThe Lancet, 2018
- Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort studyAnnals Of The Rheumatic Diseases, 2017
- Myasthenia triggered by immune checkpoint inhibitors: New case and literature reviewNeuromuscular Disorders, 2017
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisBMC Medicine, 2015